Kite, A Gilead Company

This early-stage study is testing a new CAR-T cell therapy called KITE-197 for adults with aggressive large B-cell lymphoma that has returned or stopped responding to standard treatments. The study first aims to find a safe dose, then tests how well that dose works at putting the…

This is an early-stage study testing a new personalized cell therapy called KITE-363 for people with severe autoimmune diseases that haven't improved with standard treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells, which …

This study is testing a personalized immune cell therapy called axicabtagene ciloleucel (a type of CAR-T therapy) against standard treatments for follicular lymphoma that has come back or stopped responding to previous therapies. It involves about 230 participants and aims to see…

This study is testing a personalized treatment called anitocabtagene-autoleucel for adults with multiple myeloma that has returned or stopped responding to standard therapies. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and infuse them…

This study is testing an experimental treatment called KTE-X19, a type of CAR T-cell therapy, in Japanese adults whose mantle cell lymphoma or acute lymphoblastic leukemia has returned or not responded to prior treatments. The main goals are to see how well the treatment works an…

This study is testing the safety and effectiveness of a personalized cell therapy called KTE-X19 for children and young adults up to age 21. The therapy is for those whose B-cell leukemia or lymphoma has come back or hasn't responded to other treatments. Doctors modify a patient'…

This early-stage study is testing experimental cell therapies for people with advanced multiple myeloma that has stopped responding to standard treatments. The main goals are to check if the treatments are safe and to find the best dose for future studies. It will involve about 4…

This study aims to learn about the long-term safety and lasting effects of several experimental cell-based cancer therapies. It will follow up to 1,000 people who have already received one of these treatments in a previous Kite-sponsored trial. The main goal is to monitor for any…